Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.

This clinical study was set-up to evaluate the antihypertensive effect of ketanserin in essential hypertension (EH) associated with asymptomatic ischemic heart disease (IHD) in twenty-seven patients. Every patient received 20-40 mg ketanserin, a selective S2 serotoninergic antagonist, twice daily, for a three-month period. The blood pressure (BP) was significantly lowered during the treatment with ketanserin, much more in female patients and elderly group.